Helen Heslop, MD

Former affiliation
  • 27609 Citations
  • 89 h-Index
1978 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Personal profile

Dr. Heslop's initial faculty appointment was as Assistant Member of the Division of Bone Marrow Transplantation in the Department of Hematology-Oncology at the St. Jude Children's Research Hospital, in Memphis in 1991. She was promoted to Associate Member in 1994. She also held an appointment as Associate Professor in the Department of Pediatrics at the University of Tennessee in Memphis. Dr. Heslop received her current appointments at the Baylor College of Medicine in Houston, Texas in 1997. She was named as the first Dan L. Duncan Chair for Baylor College of Medicine in 2006.

Research interests

Dr. Heslop's research centers on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She currently directs a Lymphoma SPORE program and a program project grant from the NCI, as well as a Specialized Center of Research from the Leukemia and Lymphoma Society. Her research focus is to develop safe and effective T-cell immunotherapies for lymphoma and other Epstein-Barr virus-associated malignancies, including Hodgkin's Disease and nasopharyngeal cancer. Dr. Heslop also runs studies using third party CTLs to treat viral infections after transplant.

Free-text keywords

  • Cancer
  • Adoptive immunotherapy
  • Effector cells
  • Hemopoietic stem cell transplantation

Fingerprint Dive into the research topics where Helen Heslop is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 18 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

CRISPR-Edited Immune Effectors: The End of the Beginning

Mo, F., Heslop, H. & Mamonkin, M., Apr 8 2020, In : Molecular Therapy. 28, 4, p. 995-996 2 p.

Research output: Contribution to journalArticle

Engineered off-the-shelf therapeutic T cells resist host immune rejection

Mo, F., Watanabe, N., McKenna, M. K., Hicks, M. J., Srinivasan, M., Gomes-Silva, D., Atilla, E., Smith, T., Ataca Atilla, P., Ma, R., Quach, D., Heslop, H. E., Brenner, M. K. & Mamonkin, M., Jan 1 2020, In : Nature Biotechnology.

Research output: Contribution to journalArticle

  • Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH

    Naik, S., Eckstein, O., Sasa, G., Heslop, H., Krance, R. A., Allen, C. & Martinez, C., Mar 1 2020, In : British Journal of Haematology. 188, 6, p. e84-e87

    Research output: Contribution to journalLetter

    1 Scopus citations

    Modulating tnfα activity allows transgenic il15-expressing cll-1 car t cells to safely eliminate acute myeloid leukemia

    Ataca Atilla, P., McKenna, M. K., Tashiro, H., Srinivasan, M., Mo, F., Watanabe, N., Simons, B. W., McLean Stevens, A., Redell, M. S., Heslop, H. E., Mamonkin, M., Brenner, M. K. & Atilla, E., Sep 16 2020, In : Journal for immunotherapy of cancer. 8, 2, e001229.

    Research output: Contribution to journalArticle

    Open Access
  • Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network

    Levine, J. E., Antin, J. H., Allen, C. E., Burroughs, L. M., Cooke, K. R., Devine, S., Heslop, H., Nakamura, R., Talano, J. A., Yanik, G. & DiFronzo, N., May 2020, In : Biology of Blood and Marrow Transplantation. 26, 5, p. e94-e100

    Research output: Contribution to journalEditorial